Drug Search Results
Using advanced filters...
Advanced Search [+]

Avosentan

Alternative Names: avosentan, spp-301, spp301, spp 301
Clinical Status: Inactive
Latest Update: 2023-02-08
Latest Update Note: PubMed Publication

Product Description

a predominant ETAreceptor antagonist (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2831858/)

Mechanisms of Action: ETa Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Speedel Pharma
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 3: Diabetic Nephropathy|Kidney Failure, Chronic

Phase 2: Kidney Diseases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

2008-000786-32

P2

Completed

Kidney Diseases

2009-09-11

2022-03-12

Treatments

ASCEND

P3

Terminated

Diabetic Nephropathy

2006-12-18

2022-03-12

Treatments

SPP301CRD15

P3

Terminated

Diabetic Nephropathy|Kidney Failure, Chronic

None

2019-03-21

Treatments